Search results for "tablets"

showing 10 items of 83 documents

Effects of different cellulose derivatives on drug release mechanism studied at a preformulation stage

2003

As a matter of fact, in vitro dissolution is well known to be the method of choice for the pharmaceutical industry to develop effective medicines. However, many experiments must be performed all along a new product life and they represent an overcharge of work for researchers. The purpose of this paper was to assess the relevance of new parameters obtained during preformulation stage by Nuclear Magnetic Resonance (NMR) experiments to better understand drug release mechanism. This study was carried out with three cellulose derivatives currently used as carrier matrices (Microcrystalline cellulose (MCC), Hydroxypropylmethyl cellulose (HPMC) and Ethyl cellulose (EC)). Granules and tablets were…

Magnetic Resonance SpectroscopyChemistry PharmaceuticalPharmaceutical ScienceMethylcelluloseDosage formExcipientschemistry.chemical_compoundHypromellose DerivativesTheophyllineEthyl celluloseOrganic chemistrySolubilityCelluloseCelluloseDrug CarriersNuclear magnetic resonance spectroscopyHypromellose DerivativesMicrocrystalline cellulosePharmaceutical PreparationsSolubilitychemistryChemical engineeringMicroscopy Electron ScanningPowdersDrug carrierAlgorithmsTabletsJournal of Controlled Release
researchProduct

IVIVC in oral absorption for fenofibrate immediate release tablets using a dissolution/permeation system.

2009

ABSTRACT: The usefulness of a dissolution/permeation (D/P) system to predict the in vivo performance of solid dosage forms containing the poorly soluble drug, fenofibrate, was studied. Biorelevant dissolution media simulating the fasted and fed state conditions of the human gastrointestinal tract were used in order to simulate the effect of food on the absorption of fenofibrate. Moreover, the results obtained from the D/P system were correlated with pharmacokinetic parameters obtained following in vivo studies in rats. The in vitro parameter (amount permeated in the D/P system) reflected well the in vivo performance in rats in terms of AUC and C max of fenofibric acid. This study thus demon…

MaleChemistry PharmaceuticalPharmaceutical ScienceAdministration OralAbsorption (skin)PharmacologyDosage formPermeabilityAbsorptionIVIVCPharmacokineticsFenofibrateIn vivoOral administrationmedicineAnimalsHumansRats WistarHypolipidemic AgentsFenofibrateChemistryPermeationRatsSolubilityCaco-2 Cellsmedicine.drugTabletsJournal of pharmaceutical sciences
researchProduct

Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabin…

2019

Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg was investigated through 96 weeks in EMERALD (NCT02269917). Virologically-suppressed, HIV-1-positive treatment-experienced adults (previous non-darunavir virologic failure [VF] allowed) were randomized (2:1) to D/C/F/TAF or boosted protease inhibitor (PI) plus emtricitabine/tenofovir-disoproxil-fumarate (F/TDF) over 48 weeks. At week 52 participants in the boosted PI arm were offered switch to D/C/F/TAF (late-switch, 44 weeks D/C/F/TAF exposure). All participants were followed on D/C/F/TAF until week 96. Efficacy endpoints were percentage cumulative protocol-defined virologic rebound (PDVR; confirmed vira…

MaleDOLUTEGRAVIRSustained Virologic ResponseHIV InfectionsGastroenterologychemistry.chemical_compound0302 clinical medicineMedicine and Health SciencesEmtricitabine030212 general & internal medicinePharmacology & PharmacyDarunavir0303 health sciencesAlanineDrug SubstitutionCobicistatEmtricitabine Tenofovir Disoproxil Fumarate Drug CombinationLamivudineAntiretroviralsMiddle AgedViral LoadOPEN-LABEL3. Good healthWEIGHT-GAINDrug CombinationsTreatment OutcomeDolutegravirNON-INFERIORITYFemaleSafetyViral loadLife Sciences & Biomedicinemedicine.drugTabletsAdultmedicine.medical_specialtyEfficacyAnti-HIV AgentsRITONAVIREmtricitabineTENOFOVIR ALAFENAMIDELAMIVUDINETenofovir alafenamideSingle-tablet regimen03 medical and health sciencesInternal medicineVirologymedicineVIH (Virus)HumansSwitch studyProtease InhibitorsTenofovirDarunavirAgedPharmacologyScience & Technology030306 microbiologybusiness.industryHIV (Viruses)AdenineDarunavir/cobicistat/emtricitabine/TAFAntiretroviral agentsCOBICISTATMAINTENANCEchemistry[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieHIV-1RitonavirCobicistat[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologiebusinessRESISTANCE
researchProduct

Buccal Delivery of Methimazole as an Alternative Means for Improvement of Drug Bioavailability: Permeation Studies and Matrix System Design

2012

The aim of this study was to investigate the potential for systemic administration of Methimazole (MMI) through the buccal mucosa as an alternative route for drug delivery. Considering that the most important restriction in buccal drug delivery could be the low permeability of the mucosa, the ability of MMI to cross the mucosal barrier was assessed. Permeation of MMI through porcine buccal mucosa was investigated ex vivo using Franz type diffusion cells, buffer solution simulating saliva or natural human saliva as donor phase. The collected data suggested that buccal mucosa does not hinder MMI diffusion and the drug crosses the membrane (J(s) = 0.068 mg cm(-2) h(-1) and K(p) = 0.065 cm h(-1…

MaleDrugSwinemedia_common.quotation_subjectAcrylic ResinsBiological AvailabilityPharmacologyPermeabilityDosage formDiffusionExcipientsDrug Delivery SystemsAntithyroid Agentsstomatognathic systemDrug DiscoveryAnimalsHumansSalivamedia_commonPharmacologyMethimazoleChromatographyChemistryMouth MucosaAdministration BuccalBuccal administrationPermeationBioavailabilitySolubilityDrug deliverySystemic administrationEx vivoTabletsCurrent Pharmaceutical Design
researchProduct

Efficacy of a House Dust Mite Sublingual Allergen Immunotherapy Tablet in Adults With Allergic Asthma: A Randomized Clinical Trial.

2016

Importance The house dust mite (HDM) sublingual allergen immunotherapy (SLIT) tablet is a potential novel treatment option for HDM allergy–related asthma. Objectives To evaluate the efficacy and adverse events of the HDM SLIT tablet vs placebo for asthma exacerbations during an inhaled corticosteroid (ICS) reduction period. Design, Settings, and Participants Double-blind, randomized, placebo-controlled trial conducted between August 2011 and April 2013 in 109 European trial sites. The trial included 834 adults with HDM allergy–related asthma not well controlled by ICS or combination products, and with HDM allergy–related rhinitis. Key exclusion criteria were FEV 1 less than 70% of predicted…

MaleExacerbationlaw.invention0302 clinical medicineRandomized controlled triallawAdrenal Cortex HormonesSurveys and Questionnaires030212 general & internal medicineRhinitisAged 80 and overbiologyPyroglyphidaeDustGeneral MedicineMiddle AgedTreatment OutcomeAsthma Control QuestionnaireAnesthesiaDisease ProgressionFemaleImmunotherapyTabletsAdultmedicine.medical_specialtyAllergen immunotherapyAdolescentAdministration SublingualPlacebo03 medical and health sciencesYoung AdultDouble-Blind MethodInternal medicineAdministration InhalationmedicineAnimalsHumansAlbuterolAntigens DermatophagoidesAdverse effectAdrenergic beta-2 Receptor AgonistsAsthmaAgedHouse dust mitebusiness.industryAllergensbiology.organism_classificationmedicine.diseaseAsthma030228 respiratory systemImmunoglobulin GQuality of LifebusinessJAMA
researchProduct

The use of fentanyl buccal tablets for breakthrough pain by using doses proportional to opioid basal regimen in a home care setting.

2013

Abstract The dose of rapid onset opioids to be given for breakthrough cancer pain (BTcP) is controversial. Dose proportional to the basal opioid regimen seem to be safe and effective in hospital units. However, data in other less protected settings, like home care, are lacking. The aim of this open-label study was to assess the efficacy and safety in a group of patients with BTcP followed at home, after giving a dose of fentanyl buccal tablets (FBT) proportional to the opioid basal regimen, skipping the steps for dose titration. Consecutive patients admitted to a home care program presenting BTcP episodes and receiving stable doses of opioids for background pain were selected. Data from fou…

MalePain medicineSettore MED/41 - AnestesiologiaOpioidSettore MED/42 - Igiene Generale E ApplicataHome careFentanylDose-Response RelationshipBuccalBreakthrough-episodic painNeoplasmsmedicine80 and overHumansCancer painAdverse effectAgedPain MeasurementAged 80 and overAnalgesicsDose-Response Relationship Drugbusiness.industryBreakthrough PainAdministration BuccalBuccal administrationMiddle AgedFentanyl buccal tabletHome Care ServicesAnalgesics OpioidOpioidsFentanylRegimenTreatment OutcomeBasal (medicine)OpioidOncologyCancer pain; Breakthrough-episodic pain; Fentanyl buccal tablet; Opioids; Home careAnesthesiaAdministrationFemaleBreakthrough-episodic pain; Cancer pain; Fentanyl buccal tablet; Home care; Opioids; Administration Buccal; Aged; Aged 80 and over; Analgesics Opioid; Breakthrough Pain; Dose-Response Relationship Drug; Female; Fentanyl; Home Care Services; Humans; Male; Middle Aged; Neoplasms; Pain Measurement; Tablets; Treatment Outcome; OncologyDrugCancer painbusinessmedicine.drugTablets
researchProduct

An evaluation of the efficacy of a topical gel with Triester Glycerol Oxide (TGO) in the treatment of minor recurrent aphthous stomatitis in a Turkis…

2017

Background Triester glycerol oxide gel (Protefix® Queisser Pharma, Germany) is a new topical agent that has the property of adherence to the oral mucosa by forming a lipid film which protects against mechanical trauma and may help to reduce oral tissue moisture loss and inflammation. The aim of this clinical trial was to determine the efficacy of a topical TGO gel and to also compare it with triamcinolone acetonide pomade in the treatment of minor recurrent aphthous stomatitis. Material and Methods This study was a randomized, double-blind, placebo-controlled clinical trial and 180 patients with the complaint of minor aphthous ulcers were enrolled in this study. The sociodemographic data an…

MaleTriamcinolone acetonideTurkeyAdministration TopicalTABLETStriamcinolone acetonideminor recurrent aphthous stomatitisDISEASEOintmentsULCERATION0302 clinical medicineRecurrenceOral mucosaYoung adultMiddle Aged:CIENCIAS MÉDICAS [UNESCO]030205 complementary & alternative medicineTreatment Outcomemedicine.anatomical_structureULCERSCohortUNESCO::CIENCIAS MÉDICASTopical therapyFemaleStomatitis Aphthousmedicine.drugAdultmedicine.medical_specialtyAdolescentRecurrent aphthous stomatitisPlaceboDouble blindYoung Adult03 medical and health sciencesDouble-Blind MethodInternal medicinemedicinetriester glycerol oxideMANAGEMENTHumansGlucocorticoidsGeneral DentistryAgedOral Medicine and Pathologybusiness.industryResearch030206 dentistrySurgeryClinical trialOtorhinolaryngologySurgeryLASERbusinessGelsPASTE
researchProduct

Performance of Multilayered Particles: Influence of a Thin Cushioning Layer

2005

Nowadays, oral dosage forms with controlled release kinetics have known an increasing interest. The polymer coating of drug-loaded particles is one of the most common methods used for controlling drug delivery. Such multilayered particles could be either filled into capsules or compressed into tablets for their oral administration. However, many studies have noticed that coating films are damaged during the compression process, leading to significant changes in drug release profiles. The aims of this study were to investigate the effects of a thin cushioning layer [made of HydroxyPropylMethyl Cellulose (HPMC)] applied on coated theophylline particles upon particle characteristics, tablet pr…

Materials scienceChemistry PharmaceuticalDrug CompoundingPharmaceutical ScienceExcipientMethylcelluloseengineering.materialDosage formExcipientsHypromellose DerivativesTheophyllineCoatingDrug DiscoverymedicineComposite materialCellulosePharmacologyOrganic ChemistryCushioningControlled releaseSolubilityDrug deliveryengineeringParticleTablets Enteric-CoatedLayer (electronics)medicine.drugDrug Development and Industrial Pharmacy
researchProduct

Preformulation: Effect of Moisture Content on Microcrystalline Cellulose (Avicel PH-302) and Its Consequences on Packing Performances

1999

This study evaluates the influence of moisture content on the packing performances of a new grade of microcrystalline cellulose (MCC) (Avicel PH-302) either by classical method or by an unconventional compression technique (constant volume reduction of powder bed). An increase in moisture content decreases the apparent density of the powder bed, resulting from interparticulate friction enhancement. This modification of apparent density seems to be the main effect caused by the presence of humidity, which explains the variations of compression properties, like an increase of powder plasticity generally observed in the experimental conditions.

Materials scienceChemistry PharmaceuticalPharmaceutical SciencePlasticityDosage formExcipientschemistry.chemical_compoundDrug DiscoveryCelluloseCelluloseWater contentPharmacologyChromatographyOrganic ChemistryWaterHumidityCompression (physics)Microcrystalline celluloseKineticschemistryChemical engineeringStress MechanicalParticle sizePowdersRheologyPlasticsTabletsDrug Development and Industrial Pharmacy
researchProduct

Comparative study of the lubricant performance of Compritol 888 ATO either used by blending or by hot melt coating.

2003

Compritol 888 ATO is used as a lubricant in oral solid dosage formulations. It can also be used as a hot melt coating agent sprayed onto a powder. In this study, we compare the lubricant performance of Compritol 888 ATO either used by classical blending or by hot melt coating onto Lactopress by compression tests. In physical mix, the Compritol concentration does not affect the compressibility. The same compressibility is obtained with lactose coated by 0.5 or 1% of Compritol, but a higher compressibility can be observed with 2 and 3%. Cohesiveness of lactose depends on the process: hot melt coating induces a decrease of tablet tensile strength. In terms of forces transmission during compres…

Materials scienceCompressive StrengthChemistry PharmaceuticalDrug CompoundingFatty AcidsMixing (process engineering)Pharmaceutical ScienceAdministration OralLactoseengineering.materialExcipientsHeatingCompressive strengthCoatingUltimate tensile strengthLubricationLubricationCompressibilityengineeringHot melt coatingLubricantComposite materialPowdersTabletsInternational journal of pharmaceutics
researchProduct